ClinicalTrials.gg
CompletedNCT04109313Updated Jun 20, 2024Results posted

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

A Phase 2 interventional study of LOU064 in Chronic Spontaneous Urticaria, sponsored by Novartis Pharmaceuticals. Completed at 69 sites in 15 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
229
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing remibrutinib in Chronic Urticaria — 2 open to participants now, 6 under way, 5 of them phase 3. remibrutinib · Chronic Urticaria.

Enrollment
8th of 12
229 · median 347
Started
2019
with 1 other
Phase 2
3 of 12
1 open now
Registered
2nd of 12
by date
Lead sponsor
12 of 12
Novartis Pharmaceuticals

Among the 12 studies testing remibrutinib in Chronic Urticaria, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 2, and was the 2nd registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

2 of the 12 studies testing remibrutinib in Chronic Urticaria are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About remibrutinib

remibrutinib: first FDA approval 2025 (RHAPSIDO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing remibrutinib in Chronic Urticaria, or all of them as a file.
02

Study summary

The main objective to assess the long-term safety and tolerability of LOU064 in patients with chronic spontaneous urticaria (CSU) who have participated in study CLOU064A2201 (NCT03926611)

Read the detailed description

This was an open-label, single-arm, multicenter, long-term safety and tolerability extension study for CSU patients rolling over from study CLOU064A2201 (NCT03926611).

Subjects rolling over from CLOU064A2201 with a weekly Urticaria Activity Score (UAS7)\<16 after the follow-up period at Week 16 were further followed up without receiving LOU064 for up to 12 weeks (observational period). If there was a relapse (UAS7≥16 at least once), the 12-week observational period was terminated, and subjects entered the treatment period. Subjects who never relapsed within 12 weeks completed the study after the observational period without treatment.

Subjects who rolled over from CLOU064A2201 with a UAS7≥16 at Week 12 or Week 16, as well as those subjects who relapsed during the 12-week observational period, were treated with 100 mg LOU064 twice a day (b.i.d.) open-label for 52 weeks. No background medication with a second-generation H1-antihistamine was permitted up to Week 4 of the treatment period. Subjects who completed the treatment period or who discontinued treatment early were followed-up for a minimum duration of 4 weeks. Subjects who had a UAS7≤6 at Week 52 of the treatment period had their follow-up period extended until relapse (UAS7≥16) for up to a total of 16 weeks.

03

Conditions studied

  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • Chronic spontaneous urticaria
  • BTK Inhibitor
  • Long term safety
  • Urticaria activity score
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must provide written prior to any assessments.
  • Participants must be willing and able to complete a daily symptom eDiary throughout the study and adhere to the study visit schedules.
  • Participants transitioning from the CLOU064A2201 trial must have completed either the Week 12 visit (end of treatment period) or the Week 16 visit (end of follow-up period). They will be assigned to either the treatment period or the observational period based on their UAS7 score (average score from the 7 days prior to the respective visit) as follows:

    1. Participants transitioning at Week 12 of CLOU064A2201 with a UAS7 score of ≥16 will be allocated to the treatment period.
    2. Participants transitioning at Week 16 of CLOU064A2201 with a UAS7 score of ≥16 will be allocated to the treatment period.
    3. Participants transitioning at Week 16 of CLOU064A2201 with a UAS7 score of \<16 will be allocated to the observational period.

Key Exclusion Criteria:

  • Participants with a clearly defined predominant or sole trigger for their chronic urticaria, such as chronic inducible urticaria (including symptomatic dermographism, cold-induced, heat-induced, solar-induced, pressure-induced, delayed pressure-induced, aquagenic-induced, cholinergic-induced, or contact-induced urticaria).
  • Participants with other diseases presenting with urticaria or angioedema symptoms, including but not limited to urticaria vasculitis, urticarial pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria, or acquired/drug-induced urticaria.
  • Participants with any other skin disease associated with chronic itching that, in the opinion of the investigator, could affect the study evaluations and results, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or psoriasis.
  • Participants with a history or current diagnosis of abnormalities that indicate a significant safety risk for their participation in the study, including:
  • Concomitant cardiac arrhythmias (e.g., sustained ventricular tachycardia) and clinically significant second or third-degree AV block without a pacemaker.
  • History of familiar long syndrome or a known family history of Torsades de Pointes.
  • Resting heart rate (as determined by physical exam or 12-lead ECG) below 50 bpm.
  • Resting QTcF interval ≥450 msec (in males) or ≥460 msec (in females) at day 1 of the treatment period or inability to determine the QTcF interval.
  • Use of agents known to prolong the QT interval, unless they can be permanently discontinued for the duration of the study.
  • Participants with a significant risk of bleeding or coagulation disorders.
  • Participants with a known or suspected history of an ongoing, chronic, or recurrent infectious disease, including but not limited to opportunistic infections (e.g., tuberculosis, atypical mycobacterioses, listeriosis, or aspergillosis), , or /C.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    All participants

    Participants with UAS7\<16 at Week 16 of CLOU064A2201 were followed up to 12 weeks without receiving treatment (observational period). If participants relapsed (UAS7≥16 at least once), they were transitioned to the treatment period. Otherwise, they were discontinued from the study. Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered 100 mg of LOU064 b.i.d. open-label for up to 52 weeks.

    Drug: LOU064

Interventions

  • DrugLOU064

    Participants with a UAS7≥16 at Week 12 or Week 16 in the CLOU064A2201, as well as participants who experienced a relapse during the 12-week observational period, were administered LOU064 50mg capsules b.i.d. (i.e. two capsules of LOU064 50mg in the morning and two capsules of LOU064 50mg in the evening) from Day 1 up to Week 52 of the Treatment period.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (AEs)

    An AE refers to any undesirable medical occurrence, such as an unintended sign (including abnormal laboratory findings), symptom, or disease, experienced by a participant. Serious AEs (SAEs) is defined as any AE that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or any other medically significant condition. Treatment-emergent AEs were defined as AEs that either begin on the same day or after the first dose of study medication during the treatment period in the extension study or worsen on the same day or after the first dose of study medication in the extension study and within the minimum of either 28 days post last dose or the end of the study visit. The number of participants with treatment-emergent AEs was summarized.

    Time frame: From first dose of treatment up to 28 days after last dose, assessed up to 56 weeks

Secondary outcomes

  1. Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 of the Treatment Period

    The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. The change from baseline in UAS7 at Week 4 of the treatment period was calculated. A negative change score from baseline indicates improvement. The UAS7 at baseline was considered as the UAS7 derived over the last 7 days before day 1 of the treatment period.

    Time frame: Baseline, Week 4 of treatment period

  2. Percentage of Participants With Well-controlled Disease (UAS7≤6) at Week 4 of the Treatment Period

    The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. Missing values were imputed by non-responder imputation method regardless of the reason for missingness. The percentage of subjects with UAS7≤ 6 at Week 4 of the treatment period was calculated. The 90% confidence interval was derived based on the score method with continuity correction.

    Time frame: Week 4 of the treatment period

  3. Percentage of Participants With Complete Response (UAS7=0) at Week 4 of the Treatment Period

    The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. Missing values were imputed by non-responder imputation method regardless of the reason for missingness. The percentage of subjects with UAS7= 0 at Week 4 of the treatment period was calculated. The 90% confidence interval was derived based on the score method with continuity correction.

    Time frame: Week 4 of the treatment period

  4. Percentage of Participants With Well-controlled Disease (UAS7≤ 6) Overtime

    The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. The percentage of subjects with UAS7≤ 6 during the treatment period was calculated. The 90% confidence interval was derived based on the score method with continuity correction. The UAS7 at baseline was considered as the UAS7 derived over the last 7 days before day 1 of the treatment period.

    Time frame: From baseline until Week 52 of the treatment period

  5. Change From Baseline in UAS7 Overtime

    The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. The change from baseline in UAS7 during the treatment period was calculated. A negative change score from baseline indicates improvement. The UAS7 at baseline was considered as the UAS7 derived over the last 7 days before day 1 of the treatment period.

    Time frame: From baseline until Week 52 of the treatment period

07

Results

Posted Sep 29, 2023

Participant flow

229 subjects were enrolled in the observational period or the treatment period across 72 sites in 15 countries. One subject was a screening failure and, as a result, was not enrolled in either the observational or treatment period.

Participant flow — Overall Study
MilestoneAll Participants
Started229
Treatment-free cohort68
Treatment cohort194
Completed188
Not completed41
Withdrew: Pregnancy1
Withdrew: Adverse event11
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up1
Withdrew: Physician decision2
Withdrew: Subject decision13
Withdrew: Covid-19 situation2

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (AEs)

An AE refers to any undesirable medical occurrence, such as an unintended sign (including abnormal laboratory findings), symptom, or disease, experienced by a participant. Serious AEs (SAEs) is defined as any AE that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or any other medically significant condition. Treatment-emergent AEs were defined as AEs that either begin on the same day or after the first dose of study medication during the treatment period in the extension study or worsen on the same day or after the first dose of study medication in the extension study and within the minimum of either 28 days post last dose or the end of the study visit. The number of participants with treatment-emergent AEs was summarized.

Time frame:
From first dose of treatment up to 28 days after last dose, assessed up to 56 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (AEs)
ParticipantsTreated Cohort
AEs139
Deaths0
Non-fatal Serious AEs (SAEs)6
SAE(s)6
Discontinued treatment due to any AE(s)11
Discontinued treatment due to any SAE(s)2
Treatment interruption due to AE(s)13
Treatment interruption due to SAE(s)1
SecondaryChange From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 of the Treatment Period

The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. The change from baseline in UAS7 at Week 4 of the treatment period was calculated. A negative change score from baseline indicates improvement. The UAS7 at baseline was considered as the UAS7 derived over the last 7 days before day 1 of the treatment period.

Time frame:
Baseline, Week 4 of treatment period
Reported as:
Mean · Score on a Scale
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 of the Treatment Period
Score on a ScaleTreated Cohort
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 of the Treatment Period-17.58 ± 13.400
SecondaryPercentage of Participants With Well-controlled Disease (UAS7≤6) at Week 4 of the Treatment Period

The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. Missing values were imputed by non-responder imputation method regardless of the reason for missingness. The percentage of subjects with UAS7≤ 6 at Week 4 of the treatment period was calculated. The 90% confidence interval was derived based on the score method with continuity correction.

Time frame:
Week 4 of the treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With Well-controlled Disease (UAS7≤6) at Week 4 of the Treatment Period
Percentage of participantsTreated Cohort
Percentage of Participants With Well-controlled Disease (UAS7≤6) at Week 4 of the Treatment Period51.0 (44.9 to 57.1)
SecondaryPercentage of Participants With Complete Response (UAS7=0) at Week 4 of the Treatment Period

The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. Missing values were imputed by non-responder imputation method regardless of the reason for missingness. The percentage of subjects with UAS7= 0 at Week 4 of the treatment period was calculated. The 90% confidence interval was derived based on the score method with continuity correction.

Time frame:
Week 4 of the treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Response (UAS7=0) at Week 4 of the Treatment Period
Percentage of participantsTreated Cohort
Percentage of Participants With Complete Response (UAS7=0) at Week 4 of the Treatment Period27.3 (22.2 to 33.1)
SecondaryPercentage of Participants With Well-controlled Disease (UAS7≤ 6) Overtime

The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. The percentage of subjects with UAS7≤ 6 during the treatment period was calculated. The 90% confidence interval was derived based on the score method with continuity correction. The UAS7 at baseline was considered as the UAS7 derived over the last 7 days before day 1 of the treatment period.

Time frame:
From baseline until Week 52 of the treatment period
Reported as:
Number · Percentage of participants
Percentage of Participants With Well-controlled Disease (UAS7≤ 6) Overtime
Percentage of participantsTreated Cohort
Baseline1.0 (0.2 to 3.5)
Week 137.4 (31.4 to 43.8)
Week 452.7 (46.4 to 58.8)
Week 1256.6 (50.1 to 63.0)
Week 2062.7 (56.1 to 68.9)
Week 2868.5 (61.9 to 74.5)
Week 4066.5 (59.6 to 72.7)
Week 5268.0 (61.1 to 74.3)
SecondaryChange From Baseline in UAS7 Overtime

The Urticaria Activity Score (UAS) is a composite, diary-recorded score with numeric severity intensity ratings (0=none to 3=intense/severe) for the number of wheals (hives) and the intensity of the pruritus (itch) over the past 12 hours (twice daily). The daily UAS is calculated as the average of the morning and evening scores. The UAS7 is the weekly sum of the daily UAS, which is the composite score of the intensity of pruritus and the number of wheals. UAS7 scores ranged from 0 to 42. A higher UAS7 indicated greater urticaria disease activity. A minimum of 4 out of 7 daily scores were needed to calculate the UAS7 values. Otherwise, the weekly score was missing for that week. The change from baseline in UAS7 during the treatment period was calculated. A negative change score from baseline indicates improvement. The UAS7 at baseline was considered as the UAS7 derived over the last 7 days before day 1 of the treatment period.

Time frame:
From baseline until Week 52 of the treatment period
Reported as:
Mean · Score on a Scale
Change From Baseline in UAS7 Overtime
Score on a ScaleTreated Cohort
Week 1-14.76 ± 11.502
Week 4-17.58 ± 13.400
Week 12-19.37 ± 12.502
Week 20-20.61 ± 11.634
Week 28-21.54 ± 11.525
Week 40-21.25 ± 11.400
Week 52-21.82 ± 10.699

Adverse events

Collected over In the Treated cohort, treatment-emergent AEs were collected from first dose of treatment up to 28 days post last dose, up to 56 weeks; and deaths were collected from first dose of treatment until end of study, assessed up to 68 weeks. In the Treatment-free cohort, AEs and deaths were collected from start of observation period until relapse (UAS7≥16) or end of observation period, up to 12 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment-free Cohort (Observational Period)0/68 (0%)1/68 (1.5%)0/68 (0%)
Treated Cohort (Treatment+Follow-up Period)0/194 (0%)6/194 (3.1%)56/194 (28.9%)
Most frequent serious events
Most frequent serious events
EventTreatment-free Cohort (Observational Period)Treated Cohort (Treatment+Follow-up Period)
Superficial spreading melanoma stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/680/194
COVID-19 pneumoniaInfections and infestations0/682/194
MelaenaGastrointestinal disorders0/681/194
Chest painGeneral disorders0/681/194
AppendicitisInfections and infestations0/681/194
Tibia fractureInjury, poisoning and procedural complications0/681/194
Ovarian cystReproductive system and breast disorders0/681/194
Most frequent other events
Most frequent other events
EventTreatment-free Cohort (Observational Period)Treated Cohort (Treatment+Follow-up Period)
Chronic spontaneous urticariaSkin and subcutaneous tissue disorders—22/194
COVID-19Infections and infestations—16/194
HeadacheNervous system disorders—13/194
EczemaSkin and subcutaneous tissue disorders—10/194

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Participants
Median45 (18 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female165
Male64
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
White181
Black2
Asian44
Multiple1
American Indian or Alaska Native1
08

Study locations

69 sites
  • Novartis Investigative Site
    Litchfield Park, Arizona 85340, United States
  • Novartis Investigative Site
    Little Rock, Arkansas 72205, United States
  • Novartis Investigative Site
    Mission Viejo, California 92691, United States
  • Novartis Investigative Site
    San Diego, California 92123, United States
  • Novartis Investigative Site
    Walnut Creek, California 94598, United States
  • Novartis Investigative Site
    Pembroke Pines, Florida 33028, United States
  • Novartis Investigative Site
    Owensboro, Kentucky 42301, United States
  • Novartis Investigative Site
    Ypsilanti, Michigan 48197, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63141, United States
  • Novartis Investigative Site
    Grove City, Ohio 43123, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1414AIF, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1902COS, Argentina
  • Novartis Investigative Site
    Ciudad de Mendoza, Mendoza M5500AWD, Argentina
  • Novartis Investigative Site
    Caba, 1035, Argentina
  • Novartis Investigative Site
    Edegem, Antwerpen 2650, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Edmonton, Alberta T5K 1X3, Canada
  • Novartis Investigative Site
    London, Ontario N6H 5L5, Canada
  • Novartis Investigative Site
    Niagara Falls, Ontario L2H 1H5, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1G 6C6, Canada
  • Novartis Investigative Site
    Verdun, Quebec H4G 3E7, Canada
  • Novartis Investigative Site
    Quebec, G1V 4W2, Canada
  • Novartis Investigative Site
    Prague 8, Czech Republic 180 00, Czechia
  • Novartis Investigative Site
    Prague, Prague 1 11000, Czechia
  • Novartis Investigative Site
    Tabor, 390 01, Czechia
  • Novartis Investigative Site
    Arhus C, DK 8000, Denmark
  • Novartis Investigative Site
    Copenhagen NV, 2400, Denmark
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Nantes Cedex 1, 44093, France
  • Novartis Investigative Site
    Nice Cedex, 06202, France
  • Novartis Investigative Site
    Oroshaza, Bekes 5900, Hungary
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Pecs, 7632, Hungary
  • Novartis Investigative Site
    Szolnok, 5000, Hungary
  • Novartis Investigative Site
    Ichinomiya, Aichi 491-0041, Japan
  • Novartis Investigative Site
    Funabashi, Chiba 273-0031, Japan
  • Novartis Investigative Site
    Hiroshima City, Hiroshima 734-8551, Japan
  • Novartis Investigative Site
    Obihiro, Hokkaido 080 0013, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 220-6208, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 221-0825, Japan
  • Novartis Investigative Site
    Yokohama, Kanagawa 240-0013, Japan
  • Novartis Investigative Site
    Itabashi-ku, Tokyo 173-8610, Japan
  • Novartis Investigative Site
    Takaoka, Toyama 933-0871, Japan
  • Novartis Investigative Site
    Gdansk, 80 803, Poland
  • Novartis Investigative Site
    Lodz, 90-265, Poland
  • Novartis Investigative Site
    Lodz, 90-436, Poland
  • Novartis Investigative Site
    Rzeszow, 35 055, Poland
  • Novartis Investigative Site
    Warszawa, 02 777, Poland
  • Novartis Investigative Site
    Moscow, 123182, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 194354, Russian Federation
  • Novartis Investigative Site
    St.-Petersburg, 195112, Russian Federation
  • Novartis Investigative Site
    Stavropol, 355000, Russian Federation
  • Novartis Investigative Site
    Kosice, Slovak Republic 040 15, Slovakia
  • Novartis Investigative Site
    Nove Zamky, 940 34, Slovakia
  • Novartis Investigative Site
    Svidnik, 08901, Slovakia
  • Novartis Investigative Site
    Barcelona, Catalunya 08003, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03010, Spain
  • Novartis Investigative Site
    Madrid, 28006, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Istanbul, TUR 34098, Turkey
  • Novartis Investigative Site
    Denizli, 20070, Turkey
  • Novartis Investigative Site
    Talas / Kayseri, 38039, Turkey
  • Novartis Investigative Site
    Leeds, LS9 7TF, United Kingdom
  • Novartis Investigative Site
    London, SE1 9RT, United Kingdom
  • Novartis Investigative Site
    Oxford, OX3 7LJ, United Kingdom
  • Novartis Investigative Site
    Plymouth, PL6 8DH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Sep 2022, 34 months.

Results were first posted in Sep 2023, 1 year after primary completion.

Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2019
First posted
Sep 30, 2019
StartActual
Oct 24, 2019
Primary completionActual
Sep 9, 2022
CompletionActual
Sep 9, 2022
Results first posted
Sep 29, 2023
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04109313
Responsible party
Sponsor
First posted
Sep 30, 2019
Start date
Oct 24, 2019
Primary completion
Sep 9, 2022
Completion
Sep 9, 2022
Results posted
Sep 29, 2023
Last update
Jun 20, 2024

Study contacts

Novartis Pharmaceutical
study director · Novartis Pharmaceutical

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion